Skip to content

PTSD research published in 2025

Page 6 of 6: studies 101 to 118 of 118, newest first. Back to the PTSD overview

Studies

Dream Enactment Behaviour in Post-Traumatic Stress Disorder

European Journal of Psychotraumatology January 7, 2025 Cresta Asah, Hinuga Sandahl, Lone Baandrup et al. 2 citations

Background: Sleep disturbances are widely reported in Post-Traumatic Stress Disorder (PTSD). Although Dream Enactment Behaviour (DEB) has long been associated with PTSD, its high prevalence has only recently been recognized, sparking discussions about the classification of trauma-related sleep disorders. The impact of DEB on treatment outcomes in PTSD remains unexplored.Objective: To...

DOI: 10.1080/20008066.2024.2444743 (opens in new tab) Traumatic stress Dream Stress linguistics Clinical psychology +2

(2R, 6R)-hydroxynorketamine ameliorates PTSD-like behaviors during the reconsolidation phase of fear memory in rats by modulating the VGF/BDNF/GluA1 signaling pathway in the hippocampus.

Behavioural Brain Research January 5, 2025 Han Wang, Yuxuan He, Jiahao Tang et al. 5 citations

Fear memory, a fundamental symptom of post-traumatic stress disorder (PTSD), is improved by (2R, 6R)-hydroxynorketamine ((2R, 6R)-HNK) administration. However, the phase of fear memory in which the injected drug is the most effective at mitigating PTSD-like effects remains unknown. This study aimed to explore the effects of (2 R, 6 R)-HNK administration during three phases [acquisition (AP),...

DOI: 10.1016/j.bbr.2024.115273 (opens in new tab) Full text (opens in new tab) 2r 6r-hydroxynorketamine Acquisition Extinc-tion +6

Dissociative episodes and concurrent heart rate in patients with PTSD - An ecological momentary assessment.

Psychiatry Research 2025 Sarah Beutler-Traktovenko, Marcel Franz, Judith Daniels et al.

Dissociative symptoms are a frequent complication in posttraumatic stress disorders affecting about a third of all PTSD patients. While theoretical models predict a physiological hypoarousal during posttraumatic dissociations, empirical evidence is lacking. We addressed this by studying spontaneously occurring dissociative symptoms and related heart rate changes in an ecological momentary...

Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD

Open Science Framework 2025 Mackenzie Hancock, Shambhu Prasad Adhikari, Nicole Getz preprint

This scoping review examines the emerging evidence for psilocybin-assisted therapy (PAP) in treating trauma-related disorders such as posttraumatic stress disorder (PTSD), depression, and persistent post-concussion symptoms (PPCS), with specific implications for intimate partner violence (IPV)-related brain injury and PTSD. Guided by PRISMA-ScR methodology, we systematically searched Medline,...

DOI: 10.17605/osf.io/ar2s4 (opens in new tab) Domestic violence Posttraumatic stress Psychotherapist Clinical psychology +10

Using a mobile app comprising neurofeedback-based meditation and binaural beat music to treat PTSD symptoms: A qualitative analysis.

Digital health 2025 Yun-Jung Choi, Na-Rae Lee 1 citation

There is a significant need for an effective and convenient symptom management and healing program for people experiencing post-traumatic stress disorder (PTSD) symptoms; however, research on this topic is lacking. This study explored the experiences of individuals with PTSD who used a mobile traumatic stress management app with neurofeedback-based meditation and binaural beat music to promote...

Childhood trauma and subclinical PTSD symptoms predict adverse effects and worse outcomes across two mindfulness-based programs for active depression.

PLoS One 2025 Nicholas K. Canby, Elizabeth A Cosby, Roman Palitsky et al. 10 citations

Within mindfulness-based programs (MBPs), mixed results have been found for the role of childhood trauma as a moderator of depression outcomes. Furthermore, childhood trauma and PTSD symptoms have been identified as possible risk factors for the occurrence of meditation-related adverse effects (MRAE). The present research examined multiple forms of childhood trauma and PTSD symptoms as...

Cost-effectiveness of Transcendental Meditation (TM) for treating Post-Traumatic Stress Disorder (PTSD).

PLoS One 2025 Erik J Groessl, Thomas Rutledge 1 citation

A recent trial found that Transcendental Meditation (TM) was an effective non-trauma focused treatment for veterans with Post-Traumatic Stress Disorder (PTSD). The objective of this analysis was to examine the cost-effectiveness of TM for PTSD based on the trial results. Between 2013-2017, 203 veterans with PTSD were randomized to either TM, Prolonged Exposure (PE), or to a PTSD health...

Brain stimulation enhances dispositional mindfulness in PTSD: an exploratory sham-controlled rTMS trial.

Frontiers in Psychiatry 2025 Kaveh Rayani, Andrea Grabovac, Peter Chan et al. 2 citations

Post-traumatic stress disorder (PTSD) is characterized by hypervigilance, intrusive thoughts, negative mood, and avoidant behaviors. Therapies involving mindfulness have been shown to reduce PTSD symptoms and modulate brain function. Pharmacological and brain stimulation interventions are also effective for treating PTSD. Non-invasive repeated transcranial magnetic stimulation (rTMS) of the...

Peculiarities of psycho-emotional and neurovegetative state in Ukrainian women who have experienced war-related stress and ways of its non-medicinal correction.

Wiadomosci lekarskie (Warsaw, Poland : 1960) 2025 Viktor S Matsyshyn, Kostiantyn O Apykhtin, Anatolii M Kravchenko et al.

Aim: To investigate the peculiarities of psycho-emotional and neurovegetative disorders in women exposed to war-related stress and to assess the possibilities of their correction by cognitive behavioural therapy (CBT) and Transcendental Meditation (TM). Materials and Methods: The study involved 72 women, 35 of whom had experienced high-intensity stress and 37 of whom were in the control group....

MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review.

PLoS One 2025 Filip Stanicic, Vladimir Zah, Dimitrije Grbic et al. 5 citations

3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is currently being evaluated for treatment of patients with moderate or higher severity post-traumatic stress disorder (PTSD). To provide a comprehensive summary of investigational MDMA-AT and current treatments for PTSD. A search was conducted in PubMed and Embase (December 20, 2023). Populations included adults with chronic,...

Post-traumatic stress disorder in psychedelic research.

International review of neurobiology 2025 Tijmen Bostoen, Stephan Tap, Joost J. Breeksema et al. 1 citation

Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops after exposure to trauma such as combat, natural disasters, or assault. It is characterized by re-experiencing trauma, avoidance, hyperarousal, and negative alterations in cognition and mood. Since its formal inclusion in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-III in 1980, PTSD has...

Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm.

Journal of Psychopharmacology 2025 Henry A MacConnel, Mitch Earleywine, Steven Radowitz 5 citations

Traditional treatments for post-traumatic stress disorder (PTSD) often show limited success with high dropout. Ketamine, an N-methyl-D-aspartate antagonist known for rapid antidepressant effects, has decreased PTSD symptoms in some studies but not in others. Administering ketamine in ways that parallel psychedelic-assisted treatments-including preparatory, integration, sensory immersion, and...

DOI: 10.1177/02698811241286726 (opens in new tab) Full text (opens in new tab) PTSD Ketamine-assisted psychotherapy Psychedelic Kap +1

MDMA and MDMA-Assisted Therapy.

American Journal of Psychiatry 2025 Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray et al. 47 citations

MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the...

Efficacy of fluoxetine and (R,S)-ketamine in attenuating conditioned fear behaviors in male mice.

Journal of Pharmacology and Experimental Therapeutics 2025 Megan Wells, Jan Hoffmann, Autumn Stage et al. 1 citation

Post-traumatic stress disorder (PTSD) is caused by exposure to a traumatic or stressful event. Symptoms related to this disorder include persistent re-experiencing of memories and fear of generalization. Current pharmacological treatments for PTSD are insufficient, with fewer than 30% of patients reporting symptom remission. This study aims to determine the efficacy of acute (R,S)-ketamine and...

Bringing MDMA-assisted therapy for PTSD to traditional healthcare systems: tending to set and setting.

Frontiers in Psychiatry 2025 Dimitri Perivoliotis, Kayla Knopp, Shannon Remick et al. 2 citations

Although effective evidence-based trauma-focused psychotherapies for posttraumatic stress disorder (PTSD) are available, a significant proportion of patients show a suboptimal response or do not complete them. MDMA-assisted therapy (MDMA-AT) for PTSD is a promising intervention currently being evaluated in numerous studies worldwide, including investigation for potential Food and Drug...

Biological treatments for co-occurring eating disorders and psychological trauma: a systematic review.

Frontiers in Psychiatry 2025 Ella van Beers, Irene de Vries, Caroline Planting et al. 2 citations

Many people with eating disorders report having experienced childhood maltreatment or a traumatic event prior to developing an eating disorder. Although many people with eating disorders have significant traumatic exposure or symptoms of post-traumatic stress disorder, very little research has examined the effects of combined treatments for this group. The purpose of this systematic review was...

Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine.

Frontiers in Psychiatry 2025 Muneeb Hashmi, Padmasini Mugunthan, Priyal Jain et al. 2 citations

Psychogenic non-epileptic seizures (PNES), or functional seizures (FS), are episodes that resemble epileptic seizures but may be psychological in origin. Unlike epileptic seizures, which are linked to abnormal electrical activity in the brain, functional seizures may be associated with psychological and/or physical distress, and do not show the same electrical patterns on an...

Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder.

Journal of Pharmacology and Experimental Therapeutics 2025 Claire E Miller, Phillip R. Zoladz 10 citations

Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that develops following exposure to a traumatic event. Individuals with this condition experience numerous physiological and behavioral alterations, including intrusive memories, avoidance of trauma-related stimuli, heightened anxiety, hypervigilance, impaired cognition, elevated resting heart rate and blood pressure,...